IFP Advisors Inc Takes Position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Key Points

• IFP Advisors Inc purchased 10,000 shares of Tonix Pharmaceuticals, amounting to an investment of approximately $179,000, reflecting a 0.16% ownership in the company as of its latest SEC filing.
• Other institutional investors, including Geode Capital Management and Jane Street Group LLC, significantly increased their stakes in Tonix Pharmaceuticals during the fourth quarter, suggesting growing institutional interest in the stock.
• Wall Street analysts are optimistic about Tonix Pharmaceuticals, with firms like Alliance Global Partners maintaining a “buy” rating amidst recent performance and potential growth forecasts for the company.

IFP Advisors Inc purchased a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,000 shares of the company's stock, valued at approximately $179,000. IFP Advisors Inc owned approximately 0.16% of Tonix Pharmaceuticals as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC acquired a new position in Tonix Pharmaceuticals during the fourth quarter worth about $40,000. Two Sigma Investments LP acquired a new position in Tonix Pharmaceuticals during the fourth quarter worth about $66,000. Northern Trust Corp acquired a new position in Tonix Pharmaceuticals during the fourth quarter worth about $162,000. Rhumbline Advisers acquired a new position in Tonix Pharmaceuticals during the first quarter worth about $244,000. Finally, Point72 Asset Management L.P. acquired a new position in Tonix Pharmaceuticals during the fourth quarter worth about $526,000. 82.26% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Tonix Pharmaceuticals

In other news, CEO Seth Lederman bought 4,000 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The shares were purchased at an average price of $21.55 per share, for a total transaction of $86,200.00. Following the completion of the transaction, the chief executive officer owned 4,005 shares in the company, valued at $86,307.75. The trade was a 80,000.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.03% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TNXP. Alliance Global Partners reiterated a "buy" rating on shares of Tonix Pharmaceuticals in a research report on Tuesday, June 3rd. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th.

Tonix Pharmaceuticals Trading Up 2.9%

Shares of TNXP stock traded up $1.09 during trading hours on Friday, hitting $38.77. The company's stock had a trading volume of 313,000 shares, compared to its average volume of 1,304,302. Tonix Pharmaceuticals Holding Corp. has a twelve month low of $6.76 and a twelve month high of $130.00. The business has a fifty day moving average of $38.64 and a 200-day moving average of $25.86. The stock has a market cap of $285.35 million, a price-to-earnings ratio of -0.02 and a beta of 2.05.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative net margin of 1,313.87% and a negative return on equity of 120.96%. The firm had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.55 million. On average, equities analysts expect that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current fiscal year.

Tonix Pharmaceuticals Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.